Update shared on 23 Nov 2025
Analysts have raised their price target for Lotus Pharmaceutical, increasing it by $0.00. Recent projections reflect higher expected revenue growth and improved profit margins, along with a lower anticipated future price-to-earnings ratio.
Valuation Changes
- Revenue Growth has increased from 36.17% to 41.64%.
- Net Profit Margin has risen slightly from 22.95% to 23.69%.
- Future P/E has fallen significantly from 10.18x to 8.49x.
- The Discount Rate remains nearly unchanged, moving marginally from 5.23% to 5.23%.
- Fair Value remains constant at NT$378.20.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.